Binet Staging System for Chronic Lymphocytic Leukemia (CLL)
ورودیهای بالینی بیمار
حداقل ۳ — حداکثر ۲۰ • واحد: g/dL
حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10³/mm³
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stage A1–1
- Stage B2–2
- Stage C3–3
The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include cervical lymphadenopathy. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions
Clinical Indication
The Binet Staging System for Chronic Lymphocytic Leukemia (CLL) is indicated for bedside clinical practice to support Stages chronic lymphocytic leukemia based on lymphadenopathy areas and hematologic parameters to predict prognosis and guide treatment decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Treatment decisions should incorporate clinical symptoms, performance status, and comorbidities.
Count lymphoid areas involved (cervical, axillary, inguinal, spleen, liver). Stage A: <3 areas + normal Hgb/platelets. Stage B: ≥3 areas + normal Hgb/platelets. Stage C: Anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelets <100×10³/mm³)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| cervical_lymphadenopathy | string | Yes | Enlarged cervical lymph nodes (neck region) |
| axillary_lymphadenopathy | string | Yes | Enlarged axillary lymph nodes (underarm region) |
| inguinal_lymphadenopathy | string | Yes | Enlarged inguinal lymph nodes (groin region) |
| splenomegaly | string | Yes | Enlarged spleen (splenomegaly) |
| hepatomegaly | string | Yes | Enlarged liver (hepatomegaly) |
| hemoglobin | float | Yes | Hemoglobin level in g/dL(g/dL) |
| platelet_count | integer | Yes | Platelet count in thousands per mm³ (×10³/mm³)(×10³/mm³) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Stage A | Low risk - <3 lymphoid areas involved, normal Hgb and platelets |
| 2–2 | Stage B | Intermediate risk - ≥3 lymphoid areas involved, normal Hgb and platelets |
| 3–3 | Stage C | High risk - Anemia (Hgb <10 g/dL) and/or thrombocytopenia (platelets <100×10³/mm³) |
Evidence-Based References (EBM)
- Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198-206.
- Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760.
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34.